Compare EPR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | CRSP |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.1B |
| IPO Year | 1997 | 2016 |
| Metric | EPR | CRSP |
|---|---|---|
| Price | $54.97 | $60.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | $57.06 | ★ $71.50 |
| AVG Volume (30 Days) | 706.8K | ★ 1.7M |
| Earning Date | 02-25-2026 | 02-10-2026 |
| Dividend Yield | ★ 6.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $707,150,000.00 | $38,337,000.00 |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $2.95 | $1,299.68 |
| P/E Ratio | $24.01 | ★ N/A |
| Revenue Growth | ★ 3.73 | N/A |
| 52 Week Low | $41.75 | $30.04 |
| 52 Week High | $61.24 | $78.48 |
| Indicator | EPR | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 68.03 | 60.82 |
| Support Level | $54.51 | $51.00 |
| Resistance Level | $56.03 | $57.99 |
| Average True Range (ATR) | 1.05 | 3.01 |
| MACD | 0.37 | 0.25 |
| Stochastic Oscillator | 84.21 | 93.26 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.